

## IPM-authored oral presentations

---

All times are listed in UTC.

### Thurs., Jan. 28, 15:00-16:00, Live channel 1

*Oral Abstract Session:* Multipurpose prevention technologies (MPTs) for prevention of HIV and pregnancy  
OA06.01. Pharmacokinetics, safety, and vaginal bleeding associated with continuous versus cyclic 90-day use of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancy (MTN)

## IPM-supported oral presentations

---

All times are listed in UTC.

### Weds., Feb. 3, 15:00-16:00, Live channel 2

*Oral Abstract Session:* Interacting pandemics: The impact of COVID on HIV research and programmes  
OA13.01. Implementing a rapid response to the COVID-19 global pandemic in MTN-034/REACH: an HIV prevention trial among adolescent girls and young women in Africa (MTN)

### Weds., Feb. 3, 17:30-18:30, Live channel 2

*Oral Abstract Session:* Bottoms up: New insights about rectal infections and HIV/STI prevention

- OA16.03. Comparing Applicator vs. "As Lubricant" Delivery of Rectal Dapivirine Gel (MTN-033) (MTN)
- OA16.05. A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026) (MTN)

### Weds., Feb. 3, 17:30-18:30, Live channel 3

*Oral Abstract Session:* Community engagement: Enabling responsive, inclusive, accountable research  
OA17.01. Eliciting participant feedback in focus group discussions to strengthen the implementation of a HIV prevention study (MTN)

## IPM-authored poster presentations

---

Posters will be viewable on an on-demand basis.

### *Dapivirine-levonorgestrel ring*

- PE08.02. Custom silicone elastomers for improved mechanical performance and reduced hormone binding in a dapivirine/levonorgestrel vaginal ring (QUB)
- PE08.03. In vitro modelling of in vivo discoloration of the dapivirine-levonorgestrel vaginal ring using a range of simulated vaginal and menstrual fluids (QUB)

### *DS003-based products*

- PE08.02. Formulation development of an ethylene vinyl acetate ring for sustained release of the experimental entry inhibitor DS003 (QUB)
- PE24.01. Efficacy of a Vaginal Ring containing the gp120 Blocker DS003 in Pigtailed Macaques (IPM)

## IPM-supported poster presentations

---

Posters will be viewable on an on-demand basis.

### ***Dapivirine ring*** – all posters below authored by MTN

- PE01.10. Sharing objective measures of adherence to a vaginal microbicide promoted candor about actual use and bolstered motivation to prevent HIV during MTN-025/HOPE
- PE01.14. Community beliefs and practices during pregnancy and their potential effect on HIV prevention products use in Sub Saharan Africa
- PE01.15. Choice Period Counselling for Dapivirine Vaginal Ring and Truvada in MTN-034 Study; Experiences of Counsellors at MU-JHU CRS Site Kampala, Uganda
- PE01.17. Does the ring work? Perceptions and understandings of the efficacy of a vaginal ring for HIV prevention amongst women participating in the MTN-032/AHA study
- PE01.19. Counselors' acceptability of adherence counseling session recording, fidelity monitoring, and feedback in a multi-site HIV prevention study in four African countries
- PE01.20. Demystifying myths and misconceptions about use of the Dapivirine Vaginal Ring and Truvada among adolescent girls and young women in the MTN-034 study; Observations from Kampala site
- PE01.26. Using emoji stickers to understand opinions of the dapivirine vaginal ring for HIV prevention among female end-users and their male partners
- PE01.28. Grandmothers as key influencers on pregnant and breastfeeding women's health- and HIV prevention-related decision making in Johannesburg, South Africa
- PE04.01. Correlates of Dapivirine vaginal ring uptake among women participating in an open label extension trial-MTN-025/HOPE
- PE05.01. Recruiting Adolescent Girls And Young Women Into The MTN-034 Study: Lessons Learnt from the Kampala and Johannesburg Sites
- PE05.02. Involvement of Stakeholders in Planning for and Implementing HIV Clinical Research Trials among Pregnant and Breastfeeding Women in Uganda
- PE06.01. Contraceptive uptake among adolescent girls and young women pre-screened for the MTN-034/ REACH study
- PE12.01. Integration of gender-based violence screening and support into the research clinic setting: experiences from an HIV prevention open label extension trial in sub-Saharan Africa
- PE14.02. HIV Drug Resistance Assessment among Seroconverters from the MTN-025/HOPE Open-Label Dapivirine Vaginal Ring Study
- PE19.01. Population-level correlation between incidence of selected sexually transmitted infections and HIV-1 among women participating in HIV pre-exposure prophylaxis trials in Africa
- PE25.02. Impact of women's home environment on use of the dapivirine ring for HIV prevention in MTN-025/HOPE
- PE25.03. Patterns of Adherence Among South African Women in a Phase III Randomized Controlled Trial of a Dapivirine Vaginal Ring for HIV-1 Prevention

### ***Dapivirine rectal gel***

- PE01.11. Experiences Participating in Rectal Microbicide Clinical Trials: Insight from MTN-026 and MTN-033 (MTN)

## Publication-only abstracts

---

- PU01.09. Supporting Adolescent Girls and Young Women to Adhere to Oral PrEP; Experiences of counsellors at the Kampala site (*MTN*)
- PU01.12. Improving clinic visit efficiency to support retention of Adolescent Girls and Young Women in the MTN-034 study at Kampala site, Uganda (*MTN*)
- PU08.03. New in vitro release test methods for the dapivirine vaginal ring (*QUB*)
- PU25.01. Social disclosures in relation to perceived HIV protection provided by the dapivirine vaginal ring (*MTN*)
- PU25.02. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention (*MTN*)